- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-1459
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Zona incerta as a therapeutic target in Parkinson’s disease ; day:2 ; month:8 ; year:2019 ; pages:1-16
Journal of neurology ; (2.8.2019), 1-16
- Creator
-
Ossowska, Krystyna
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00415-019-09486-8
- URN
-
urn:nbn:de:101:1-2019122618050988521835
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ossowska, Krystyna
- SpringerLink (Online service)
Other Objects (12)
Inflammatory gut as a pathologic and therapeutic target in Parkinson’s disease
Therapeutic drug monitoring in Parkinson’s disease
Genotype-driven therapeutic developments in Parkinson’s disease
Molecular chaperones and protein folding as therapeutic targets in Parkinson’s disease and other synucleinopathies
Molecular chaperones and protein folding as therapeutic targets in Parkinson’s disease and other synucleinopathies
PARK7/DJ-1 in microglia: implications in Parkinson’s disease and relevance as a therapeutic target
Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
MicroRNAs regulation in Parkinson’s disease, and their potential role as diagnostic and therapeutic targets
The CD200R1 microglial inhibitory receptor as a therapeutic target in the MPTP model of Parkinson’s disease
Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease
Insomnia in Parkinson’s Disease: Causes, Consequences, and Therapeutic Approaches
The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s disease
Inflammatory gut as a pathologic and therapeutic target in Parkinson’s disease
Therapeutic drug monitoring in Parkinson’s disease
Genotype-driven therapeutic developments in Parkinson’s disease
Molecular chaperones and protein folding as therapeutic targets in Parkinson’s disease and other synucleinopathies
Molecular chaperones and protein folding as therapeutic targets in Parkinson’s disease and other synucleinopathies
PARK7/DJ-1 in microglia: implications in Parkinson’s disease and relevance as a therapeutic target
Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
MicroRNAs regulation in Parkinson’s disease, and their potential role as diagnostic and therapeutic targets
The CD200R1 microglial inhibitory receptor as a therapeutic target in the MPTP model of Parkinson’s disease
Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease
Insomnia in Parkinson’s Disease: Causes, Consequences, and Therapeutic Approaches
The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s disease
Inflammatory gut as a pathologic and therapeutic target in Parkinson’s disease
Therapeutic drug monitoring in Parkinson’s disease
Genotype-driven therapeutic developments in Parkinson’s disease
Molecular chaperones and protein folding as therapeutic targets in Parkinson’s disease and other synucleinopathies
Molecular chaperones and protein folding as therapeutic targets in Parkinson’s disease and other synucleinopathies
PARK7/DJ-1 in microglia: implications in Parkinson’s disease and relevance as a therapeutic target
Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
MicroRNAs regulation in Parkinson’s disease, and their potential role as diagnostic and therapeutic targets
The CD200R1 microglial inhibitory receptor as a therapeutic target in the MPTP model of Parkinson’s disease
Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease
Insomnia in Parkinson’s Disease: Causes, Consequences, and Therapeutic Approaches